Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the...
May 13, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on...
May 10, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris to Present at the Q2 Virtual Investor Summit

– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET CHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the...
May 06, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

–In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical...
May 05, 2021 16:35 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders

CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
May 05, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates

– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets – Pivotal Phase 3 DETECT (Study P02)...
May 03, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology CHARLESTON, S.C., May 03, 2021 (GLOBE...
April 28, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders

CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
March 25, 2021 08:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results

– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 ...
March 22, 2021 16:05 ET | Source: Aeterna Zentaris Inc

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...